Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer.
Chemohormonal therapy
Continence rate
Cytoreductive radical prostatectomy
Feasibility
Metastatic hormone-sensitive prostate cancer
Prevent local complications
Journal
Asian journal of urology
ISSN: 2214-3882
Titre abrégé: Asian J Urol
Pays: Singapore
ID NLM: 101699720
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
30
05
2020
revised:
25
10
2020
accepted:
20
01
2021
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
ppublish
Résumé
Cytoreductive radical prostatectomy (cRP) has been proposed as local treatment option in metastatic hormone-sensitive prostate cancer (mHSPC) to prevent local complications and potentially improve oncological outcomes. In this study, we examined the feasibility of a multimodal concept with primary chemohormonal therapy followed by cRP and analyzed prostate size reduction under systemic treatment, postoperative complication rates, as well as early postoperative continence. In this retrospective study, 38 patients with mHSPC underwent cRP after primary chemohormonal therapy (3-monthly luteinising hormone-releasing hormone-analogue + six cycles 3-weekly docetaxel 75 mg/m Overall, 10 (26%) patients had high volume and 28 (74%) patients had low volume disease at diagnosis, according to CHAARTED definition. Median prostate-specific antigen (PSA) decreased from 65 ng/mL (interquartile range [IQR] 35.0-124.5 ng/mL) pre-chemotherapy to 1 ng/mL (IQR 0.3-1.7 ng/mL) post-chemotherapy. Prostate gland volume was significantly reduced by a median of 50% (IQR 29%-56%) under chemohormonal therapy ( We observed a reduction of prostate volume under chemohormonal therapy going along with a low postoperative complication and high early continence rate. However, the oncologic benefit from cRP is still under evaluation.
Identifiants
pubmed: 35198399
doi: 10.1016/j.ajur.2021.04.003
pii: S2214-3882(21)00026-6
pmc: PMC8841247
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69-74Informations de copyright
© 2022 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Urol. 2015 Mar;193(3):832-8
pubmed: 25254935
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
Eur Urol. 2014 Feb;65(2):467-79
pubmed: 24321502
Eur Urol Focus. 2017 Dec;3(6):646-649
pubmed: 28753877
Ann Oncol. 2019 Dec 1;30(12):1992-2003
pubmed: 31560068
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Eur Urol. 2016 Apr;69(4):584-589
pubmed: 26277303
Eur Urol. 2014 Sep;66(3):602-3
pubmed: 24821581
Eur Urol Oncol. 2018 May;1(1):46-53
pubmed: 31100228
BJU Int. 2018 Nov;122(5):801-807
pubmed: 29727912
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
J Urol. 2017 Aug;198(2):354-361
pubmed: 28216329
J Clin Oncol. 2011 Jun 20;29(18):2574-81
pubmed: 21606419
Eur Urol. 2017 Jul;72(1):118-124
pubmed: 28385454
Eur Urol. 2014 Jun;65(6):1058-66
pubmed: 24290503
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Eur Urol. 2018 Jun;73(6):847-855
pubmed: 29475737
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
Eur Urol Focus. 2018 Jul;4(4):608-613
pubmed: 28753862
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607